drugset / Trial / NCT00354809

Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia

NCT00354809

Phase 2 Completed 68 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with primary insomnia.

Timeline

Start
2006-05
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 10 mg
Subject Casopitant Small molecule 30 mg